These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33844064)

  • 1. Validating the 'CUT score' risk stratification tool for indeterminate thyroid nodules using the Bethesda system for reporting thyroid cytopathology.
    Pinhas S; Tessler I; Bizer LP; Khalilia K; Warman M; Adi M; Halperin D; Cohen O
    Eur Arch Otorhinolaryngol; 2022 Jan; 279(1):383-390. PubMed ID: 33844064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic performances of the KWAK-TIRADS classification, elasticity score, and Bethesda System for Reporting Thyroid Cytopathology of TI-RADS category 4 thyroid nodules.
    Huang S; Meng N; Pan M; Yu B; Liu J; Deng K; Hu M; Zhou H; Qin C
    Int J Clin Exp Pathol; 2020; 13(5):1159-1168. PubMed ID: 32509090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of the 'CUT' Score for Assessing Malignancy in Bethesda 3 and 4 Thyroid Nodules in North American Population: A Retrospective Study.
    Shihabi AN; Hussein M; Toraih EA; Attia AS; Youssef MR; Elnahla A; Omar M; Shama M; Corsetti R; Kandil E
    Cancer Invest; 2022 Sep; 40(8):693-699. PubMed ID: 35549502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consistency in the Distribution of Bethesda System for Reporting Thyroid Cytology Categories Over 9 Years: A Single Institute, Retrospective Study.
    Harris M; Zloczower E; Pinhas S; Allon R; Zornitzki T; Malka L; Cohen Y; Lahav Y; Cohen O
    Endocr Pract; 2024 Jun; 30(6):546-550. PubMed ID: 38570016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology.
    Yaprak Bayrak B; Eruyar AT
    BMC Endocr Disord; 2020 Apr; 20(1):48. PubMed ID: 32293401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indeterminate nodules by the Bethesda system for reporting thyroid cytopathology in Israel: Frequency, and risk of malignancy after reclassification of follicular thyroid neoplasm with papillary-like features.
    Rosenblum RC; Shtabsky A; Marmor S; Trejo L; Yaish I; Barnes S; Yehuda M; Stern N; Silman Z; Tordjman KM
    Eur J Surg Oncol; 2019 Jul; 45(7):1182-1187. PubMed ID: 30928335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follow-Up or Surgery for Indeterminate Thyroid Nodules: Could the CUT Score Application Be a Support for Decision-Making in the Preoperative Assessment?
    Ianni F; Pascucci D; Paragliola RM; Rota CA; Perotti G; Fadda G; Pontecorvi A; Corsello SM
    Thyroid; 2020 Jan; 30(1):65-71. PubMed ID: 31552809
    [No Abstract]   [Full Text] [Related]  

  • 8. Outcomes of the Bethesda system for reporting thyroid cytopathology: Real-life experience.
    Avior G; Dagan O; Shochat I; Frenkel Y; Tessler I; Meir A; Jaffe A; Cohen O
    Clin Endocrinol (Oxf); 2021 Mar; 94(3):521-527. PubMed ID: 32981060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnostic values of BRAF(V600E) mutation analysis and Bethesda system for reporting thyroid cytopathology in thyroid nodules with TIRADS 4 and 5].
    Han Y; Zhao BW; Li SY; Lyu JG; Shou JD; Xu HS; Lou HY; Xu LL; Gao L; Xu SX; Zhu J
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Sep; 52(9):686-691. PubMed ID: 28910894
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of the Diagnostic Performance of EU-TIRADS in Discriminating Benign from Malignant Thyroid Nodules: A Prospective Study in One Referral Center.
    Kovatcheva RD; Shinkov AD; Dimitrova ID; Ivanova RB; Vidinov KN; Ivanova RS
    Eur Thyroid J; 2021 Feb; 9(6):304-312. PubMed ID: 33718254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of the Bethesda system for reporting thyroid cytopathology in community- vs. institution-performed cytology.
    Tessler I; Cohen O; Shochat I; Teitelbaum T; Dagan O; Meir A; Jaffe A; Avior G
    Am J Otolaryngol; 2022; 43(2):103341. PubMed ID: 34968817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proposal for a novel management of indeterminate thyroid nodules on the basis of cytopathological subclasses.
    Rossi M; Lupo S; Rossi R; Franceschetti P; Trasforini G; Bruni S; Tagliati F; Buratto M; Lanza G; Damiani L; Degli Uberti E; Zatelli MC
    Endocrine; 2017 Jul; 57(1):98-107. PubMed ID: 27623969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the Bethesda System for Reporting Thyroid Cytopathology in a Danish tertiary centre.
    Madsen SH; Jespersen ML; Bonnema SJ; Rolighed L; Swan KZ
    Dan Med J; 2024 May; 71(6):. PubMed ID: 38847411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACR TI-RADS and ATA US scores are helpful for the management of thyroid nodules with indeterminate cytology.
    Barbosa TLM; Junior COM; Graf H; Cavalvanti T; Trippia MA; da Silveira Ugino RT; de Oliveira GL; Granella VH; de Carvalho GA
    BMC Endocr Disord; 2019 Oct; 19(1):112. PubMed ID: 31664992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Presence of Hürthle Cells Does Not Increase the Risk of Malignancy in Most Bethesda Categories in Thyroid Fine-Needle Aspirates.
    Ren Y; Kyriazidis N; Faquin WC; Soylu S; Kamani D; Saade R; Torchia N; Lubitz C; Davies L; Stathatos N; Stephen AE; Randolph GW
    Thyroid; 2020 Mar; 30(3):425-431. PubMed ID: 32013786
    [No Abstract]   [Full Text] [Related]  

  • 16. 'Indeterminate for malignancy' (Tir3/Thy3 in the Italian and British systems for classification) thyroid fine needle aspiration (FNA) cytology reporting: morphological criteria and clinical impact.
    Pagni F; Prada M; Goffredo P; Isimbaldi G; Crippa S; Di Bella C; Leone BE;
    Cytopathology; 2014 Jun; 25(3):170-6. PubMed ID: 23937572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of the Bethesda Classification for Thyroid Fine-Needle Aspiration: Institutional Experience and Meta-analysis.
    Krauss EA; Mahon M; Fede JM; Zhang L
    Arch Pathol Lab Med; 2016 Oct; 140(10):1121-31. PubMed ID: 27684984
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Wu Y; Xu T; Cao X; Zhao X; Deng H; Wang J; Li X; Yao Q; Ye X; Shen M; Wu X
    Cancer Biol Med; 2019 Feb; 16(1):131-138. PubMed ID: 31119053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of implementation of the Bethesda System for Reporting Thyroid Cytopathology on the surgical treatment of thyroid nodules.
    Richmond BK; O'Brien BA; Mangano W; Thompson S; Kemper S
    Am Surg; 2012 Jun; 78(6):706-10. PubMed ID: 22643269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Bethesda System and the ACR TIRADS in an Endemic Goiter Region.
    Karaagac M; Sarigoz T; Ertan T; Topuz O
    Endocr Res; 2020 Nov; 45(4):226-232. PubMed ID: 32729365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.